Choosing Wisely:

Don’t offer noninvasive prenatal testing to low-risk patients or make irreversible decisions based on the results of this screening test.

Rationale and Comments: NIPT has only been adequately evaluated in singleton pregnancies at high risk for chromosomal abnormalities (maternal age >35, positive screening, sonographic findings suggestive of aneuploidy, translocation carrier at increased risk for trisomy 13, 18, or 21, or prior pregnancy with a trisomy 13, 18, or 21). Its utility in low-risk pregnancies remains unclear. False-positive and false-negative results occur with NIPT, particularly for trisomy 13 and 18. Any positive NIPT result should be confirmed with invasive diagnostic testing prior to a termination of pregnancy. If NIPT is performed, adequate pretest counseling must be provided to explain the benefits and limitations.
Sponsoring Organizations:
  • Society for Maternal-Fetal Medicine
  • Sources:
  • Expert consensus
  • Disciplines:
  • Genetic
  • Obstetrical
  • References: • American College of Obstetricians and Gynecologists Committee on Genetics. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. Obstet Gynecol. 2012 Dec;120(6):1532–4.

    Email Alerts

    Don't miss a single issue. Sign up for the free AFP email table of contents.

    Sign Up Now